June 4, 2020 / 12:05 PM / a month ago

BRIEF-Alligator Bioscience And Scandion Oncology Sign Preclinical Agreement

June 4 (Reuters) - Alligator Bioscience AB:

* ALLIGATOR BIOSCIENCE AND SCANDION ONCOLOGY SIGN PRECLINICAL AGREEMENT TO EXPLORE COMBINATION THERAPIES FOR CHEMOTHERAPY AND IMMUNO-ONCOLOGY

* EXPECTATION IS THAT SCO-101 WILL REVERT CHEMOTHERAPY RESISTANCE AND THEREBY FURTHER STRENGTHENING ANTI-TUMOR EFFECTS OF MITAZALIMAB

* RESULTS FROM STUDIES IN THIS COLLABORATION ARE EXPECTED DURING FIRST HALF OF 2021

* COMPANIES TO EXPLORE ANTI-TUMOR EFFICACY OF CD40 ANTIBODY MITAZALIMAB IN COMBINATION WITH SCO-101 AS AN ADDITION TO CHEMOTHERAPY

* TWO COMPANIES HAVE AGREED TO EXPLORE ANTI-TUMOR EFFICACY OF CD40 ANTIBODY MITAZALIMAB (ALLIGATOR BIOSCIENCE) IN COMBINATION WITH SCO-101 (SCANDION ONCOLOGY) AS AN ADDITION TO CHEMOTHERAPY IN RESISTANT PRECLINICAL TUMOR MODELS Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below